GlassScriptPhysician profile
Jeffery W Ripperda
NPI 1306869557
$15,313.82
in general payments reported to CMS, 2019-2025
56 companies · $2,263 in 2025
The $2,263 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $890 · 2021: $3,633 · 2022: $1,935 · 2023: $3,488 · 2024: $2,260 · 2025: $2,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,524 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,403 · Education: $84.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,524.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,402.50 |
| Education | $84.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $3,205.59 | 2019-2025 | Sublocade |
| Abbvie INC. | $1,411.14 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,013.70 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $1,002.91 | 2019-2024 | Prolia, Evenity, Repatha |
| Glaxosmithkline, LLC. | $967.95 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $919.54 | 2019-2025 | |
| Lilly USA, LLC | $772.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $508.37 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Novo Nordisk INC | $450.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $398.94 | 2019-2025 | |
| Dexcom, INC. | $318.47 | 2021-2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $291.28 | 2019-2024 | Yupelri |
| Amarin Pharma, INC. | $289.84 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.34 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $284.09 | 2021-2023 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Ripperda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.